Lilly posts lackluster profit but boosts full-year forecast
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Pharmaceutical
Articles
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Cook Pharmica to hire 70 workers to expand drug-making capacity
Cook Pharmica, a subsidiary of Bloomington-based medical device maker Cook Group, currently employs 575 workers who manufacture and package drugs for use in clinical trials or for sale on the market.
Lilly, partner sue Lupin over generic testosterone
Indianapolis-based Eli Lilly and Co. and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for alleged infringement of patents that cover the testosterone treatment Axiron.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Target selling pharmacy, clinic businesses to CVS Health
Target Corp. has agreed to sell its pharmacy and clinic businesses to the drugstore chain CVS Health Corp. for about $1.9 billion in a deal that combines the resources of two retailers seeking to polish their health care reputations.
Lilly to launch Lantus biosimilar in Europe in third quarter
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
Female libido drug nears approval with FDA panel’s backing
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
Indy’s Golden Age in 1920s shows way forward
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
Former Lilly partner set to pay $2.3B to settle Actos cases
Takeda Pharmaceutical Co. executives have agreed to pay more than $2.3 billion to resolve lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks, three people familiar with the accord said.
Pence signs bill expanding use of overdose drug
The new law allows Indiana residents to obtain and use a drug that can reverse heroin overdoses in their relatives, friends and loved ones.
U.S. prescription drug spending jumps 13 percent
U.S. spending on prescription drugs soared last year, driven up primarily by costly breakthrough medicines, manufacturer price hikes and a surge from millions of people newly insured due to the Affordable Care Act.
Right-to-try drug bill signed into state law
Terminally ill patients in Indiana who have run out of FDA-approved options can now turn to treatments and medicines in the testing phase.
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
‘Right to try’ trial drugs bill heads to governor’s desk
A proposal to give terminally ill patients easier access to experimental drugs not yet on pharmacy shelves has been forwarded to Gov. Mike Pence for his signature.
Indiana Senate passes ‘right-to-try’ trial drugs bill
The Indiana Senate has approved a measure that would allow terminally ill patients to use experimental drugs that are not yet on pharmacy shelves.
Senate panel considers ‘right-to-try’ trial drugs bill
An Indiana Senate committee is considering a bill that would give terminally ill patients easier access to experimental drugs that have not received full federal approval. Indiana is one of nearly two dozen states that are considering the legislation.